Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Absci Corporation ABSI

Healthcare  —  Biotechnology
9.74 (0.61) (5.89%) as of 25 Sep
Market cap
$1.8B
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Absci Corporation (ABSI) Business Profile

Updated before January 2025

Company Overview

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that specializes in harnessing the power of artificial intelligence (AI) and synthetic biology to accelerate drug discovery and development. Founded in 2011 by Sean McClain, the company is headquartered in Vancouver, Washington, USA. Absci’s mission is to redefine the drug discovery process by integrating cutting-edge AI technologies with innovative biological systems to create new therapeutics faster and more efficiently. Sean McClain, the founder and CEO, has been instrumental in driving the company’s vision of transforming the pharmaceutical industry. The leadership team also includes experienced executives and scientists who bring expertise in AI, synthetic biology, and drug development.

Core Business Segments

Absci operates in the biotechnology and pharmaceutical sectors, focusing on two primary business segments:

1. AI-Driven Drug Discovery

Absci leverages its proprietary AI platform to identify and optimize therapeutic candidates. This platform integrates machine learning algorithms with biological data to predict protein structures, optimize drug candidates, and accelerate the drug discovery process. Key offerings in this segment include:

  • Protein Design and Optimization: Absci’s AI tools enable the design of novel proteins and optimization of existing ones for therapeutic use.
  • Drug Candidate Screening: The platform rapidly screens potential drug candidates, reducing the time and cost associated with traditional methods.

2. Synthetic Biology and Biomanufacturing

Absci’s synthetic biology capabilities allow for the engineering of biological systems to produce complex proteins and biologics. This segment includes:

  • Cell Line Development: Absci develops customized cell lines for the production of therapeutic proteins.
  • Biomanufacturing Solutions: The company provides scalable biomanufacturing solutions to produce biologics efficiently.

Business Model

Absci’s business model is built on integrating its AI and synthetic biology platforms to provide end-to-end solutions for drug discovery and development. The company generates revenue through:

  • Collaborations and Partnerships: Absci partners with pharmaceutical and biotechnology companies to co-develop drug candidates and optimize biomanufacturing processes.
  • Licensing Agreements: The company licenses its AI and synthetic biology technologies to partners, earning royalties and milestone payments.
  • Service Contracts: Absci offers contract research and development services to clients in the pharmaceutical industry.

Strategic Direction

Absci is focused on expanding its capabilities and market presence through the following strategies:

  • AI Platform Expansion: The company aims to enhance its AI platform by incorporating more advanced machine learning algorithms and expanding its biological data library.
  • New Therapeutic Areas: Absci plans to explore new therapeutic areas, including oncology, rare diseases, and immunology.
  • Sustainability Goals: The company is committed to sustainable biomanufacturing practices, reducing the environmental impact of drug production.
  • Global Expansion: Absci is exploring opportunities to expand its operations and partnerships in international markets.

Competitive Landscape

Absci operates in a highly competitive industry, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • AI-Driven Drug Discovery: Companies like Insilico Medicine, Exscientia, and Atomwise are direct competitors in the AI-driven drug discovery space.
  • Synthetic Biology: Firms such as Ginkgo Bioworks and Zymergen compete with Absci in synthetic biology and biomanufacturing.
  • Traditional Pharma: Large pharmaceutical companies with in-house drug discovery and development capabilities also pose competition.

Risk Factors

Absci faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on partnerships and collaborations for revenue, making it vulnerable to changes in partner priorities.
  • Supply Chain Disruptions: Disruptions in the supply chain for raw materials and equipment could delay projects and increase costs.
  • Regulatory Challenges: The biotechnology industry is subject to stringent regulatory requirements, which could impact the approval and commercialization of Absci’s technologies.
  • Technological Risks: Rapid advancements in AI and synthetic biology could render Absci’s technologies obsolete if the company fails to innovate.

Recent Developments

Absci has made significant strides in recent years, including:

  • AI Platform Enhancements: The company recently launched an upgraded version of its AI platform, featuring improved protein design capabilities.
  • New Partnerships: Absci entered into strategic collaborations with leading pharmaceutical companies to co-develop novel therapeutics.
  • IPO: In 2021, Absci went public on the NASDAQ stock exchange, raising capital to fund its growth initiatives.
  • COVID-19 Impact: The global pandemic highlighted the importance of rapid drug discovery, increasing demand for Absci’s technologies.

Investment Considerations

Investors considering Absci should weigh the following factors:

Strengths

  • Innovative Technology: Absci’s AI and synthetic biology platforms are at the forefront of drug discovery innovation.
  • Strong Leadership: The company’s experienced leadership team provides strategic direction and industry expertise.
  • Market Potential: The global biotechnology market is growing, offering significant opportunities for Absci.

Risks

  • Financial Performance: As a relatively young company, Absci may face challenges in achieving consistent profitability.
  • Competitive Pressure: Intense competition in the biotechnology sector could impact Absci’s market share.
  • Regulatory Risks: Compliance with regulatory requirements is critical and could pose challenges.

Conclusion

Absci Corporation is a pioneering biotechnology company that combines AI and synthetic biology to revolutionize drug discovery and development. With its innovative technologies, strategic partnerships, and commitment to sustainability, Absci is well-positioned to capitalize on the growing demand for advanced therapeutics. However, investors should carefully consider the risks associated with the company’s early-stage nature and competitive landscape. Overall, Absci’s unique approach and growth potential make it a compelling player in the biotechnology industry.